Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937921 · ClinicalTrials.gov registry record
Dotarem Evaluation for Myocardial Perfusion CMR
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 90
- Enrollment target
NCT03937921: Completed study, sponsored by Medical University of South Carolina.
NCT03937921 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03937921 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation. The purpose of this study is to compare two types of contrast that patients receive during cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used in standard of care procedures, and the one administered for each patient will be randomly selected. The length of the MRI study all procedures are the same as the clinically indicated scan.
Primary Outcome
Characteristics of signal intensity changes and absolute myocardial blood flow using the MASS Research Software; signal intensity-time curves from the perfusion data
Interventions
- DRUG Gadavist 15Ml Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-07-03 |
| Est. Completion | 2024-10-31 |
What the finished NCT03937921 record still lists
NCT03937921 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gadavist 15Ml Solution for Injection is the first listed.
NCT03937921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03937921 about?
NCT03937921 is a clinical study titled "Dotarem Evaluation for Myocardial Perfusion CMR". The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotar...
What is the current status of trial NCT03937921?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2019-07-03. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT03937921?
The interventions under investigation include: Gadavist 15Ml Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT03937921?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI